Theradiag shares rise on COVID test distribution deal with Biosynex

Theradiag SA

13/01/2022 08:23

** Shares in Theradiag  ALTHE.PA  rise 2.5%, paring earlier
gains of as much as 7.8%, after the French in vitro
diagnostics-specialised company announced the signing of a
distribution deal with peer Biosynex  ALBIO.PA 
    ** Theradiag pointed to "constructive discussions" leading
to an initial two-year distribution agreement for the AMPLIQUICK
SARS-CoV-2 PCR test from Biosynex  urn:newsml:reuters.com:*:nFWN2TT00I
    ** The PCR test will be promoted in hospitals by Theradiag,
which benefits from a strong presence in the vast majority of
University Hospitals, the French group said
    ** Year-to-date, the stocks of Theradiag and Biosynex are up
by around 6% and down by about 3%, respectively

 (Reporting by Juliette Portala)
 ((juliette.portala@tr.com))